Procter & Gamble and Johnson & Johnson’s Neutrogena brand have today released details on their newest tech-enabled skin care innovations that will be showcased at CES, the huge consumer electronics show that begins this weekend in Las Vegas.
Billed as its most personalized skincare product ever, the NeutrogenaMaskiD is a patent-pending, 3D-printed sheet mask powered by user data.
According to Sebastien Guillon, global president of beauty, Johnson & Johnson Consumer Inc., consumers want personalized skincare solutions that address their skin’s unique needs. “We believe that sheet masks are the perfect opportunity to deliver on this unmet need,” he said in a press statement released in connection with launch.
Personalization with the Neutrogena MaskiD happens in three ways – first with the shape of the mask itself. Using a smartphone 3D camera, the user snaps a selfie to create a precise, multi-dimensional map of her face and the exact measurements and shape of her nose, space between the eyes, lips, and other unique physical characteristics. Next, personalized data from the Neutrogena Skin 360 system creates the virtual equivalent of a knowledgeable dermatologist and analyzes the skin’s needs, making a recommendation for what ingredients will be most beneficial and where, according to Neutrogean. Finally, using a proprietary 3D printing process, high-efficacy ingredients are printed onto the custom-fit hydrogel mask on the exact zones of the mask where they will deliver the greatest benefit for that individual.
Neutrogena MaskiD will be sold exclusively on Neutrogena.com to consumers in the United States beginning in Q3 of this year.
P&G Ventures, the startup studio within Procter & Gamble, today also released details on the n new Opté Precision Skincare System. After years of development and more than 40 patents, Opté combines the best of camera optics, proprietary algorithms, printing technology, and skincare in one device, according to P&G. It scans, detects, and corrects hyperpigmentation with precision application, according to the company.
Opté is one of the first product prototypes to emerge from P&G Ventures, which partners with startups, entrepreneurs and innovators to create new brands that solve everyday problems in product categories new to P&G.
Unlike traditional spot coverage options like makeup or serums, Opté’s proprietary technology allows it to optimize the approximately 10% of skin that needs treatment for most women without covering the 90% of skin that doesn’t, which results in a more natural, flawless look unachievable by either make-up or professional treatments, according to the company.
Opté is comprised of a wand and serum that work together. The Opté Precision Wand consists of proprietary technologies including a Micro Serum-Jet Printer that deposits 1,000 serum picoliter droplets to achieve precise coverage with 99% less product on your skin than alternatives, said P&G.
The serum, which features mineral pigments to provide immediate coverage, spot lightening skin care ingredients proven to reduce the appearance of age spots over time, and moisturizers to help your skin retain moisture and stay hydrated, according to P&G Ventures.
“Opté is one of the new brands emerging from P&G Ventures. By partnering with leading scientists and experts across industries, we have been able to create a first-of-its kind, digitally-advanced skincare device that is visibly transforming the look of skin,” said Leigh Radford, vice president and general manager of P&G Ventures. “Through P&G Ventures’ unique approach to innovation and R&D, Opté provides Procter & Gamble an entirely new category of digital skincare and technology platform from which to innovate. We’re thrilled to show consumers what we’ve been developing on a world stage such as CES.”
Opté will be available for purchase beginning in 2020, according to P&G Ventures.
Happi will be onsite next week covering CES, taking a first-hand look at both of these innovations and more. Be sure to follow our social channels (Twitter and Facebook, @HappiMagazine) updates.